MagVenture Inc., a provider of transcranial magnetic stimulation, has received clearance from the US Food and Drug Administration for a new protocol that cuts the time of each treatment session down to 3 minutes, the company announced.
Is there benefit in treating a patient with a VMAT2 inhibitor if they have already had severe tardive dyskinesia for several years? Find out here.
Using brain imaging, researchers have identified three distinct neurophysiological subtypes of depression—one of which does not respond to treatment with selective serotonin-reuptake inhibitors.
Use the links here to see all of our coverage of sessions, speakers, and posters at Psych Congress 2018.
Adding mirtazapine to a serotonin-noradrenaline reuptake inhibitor or selective serotonin reuptake inhibitor for treatment-resistant depression is no more effective than adding placebo, according to a study.
When added to an antidepressant, combination buprenorphine-samidorphan (ALKS 5461) was safe and effective in easing depressive symptoms in patients with major depressive disorder who had an inadequate response to an antidepressant alone, according to a pair of phase 3 trials.